Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect Non-Invasive Test

BioLight announced on promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.

Link to complete article

Continue reading

BioLight Reports 2015 Financial Results

BioLight Life Sciences reported operational and financial results for the year ended December 31, 2015.  Results were characterized by continued development and commercial progress in multiple markets, and the achievement of all previously announced 2015 milestones.

Operational Highlights:

  • Completed an upsized private investment and signed a strategic partnership with …

    Continue reading

Third Quarter 2015 Financial Results

BioLight today reported operational and financial results for the third quarter ended September 30, 2015.

Operational Highlights:

  • Reported first IOPtiMate™ System sales and additional distribution agreements, both in new territories.
  • Completed enrollment into the second U.S. clinical study in which TeaRx’s effectiveness is being assessed in tears …

    Continue reading

Partnership with Axella Research for CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer

BioLight announced today that its cancer diagnostics subsidiary, Micromedic Technologies, has entered into a Collaboration Agreement with Axella Research LLC, to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.

Link to …

Continue reading